Artelo Biosciences, Inc. (ARTL, Financial), a biopharmaceutical company, experienced a significant stock price increase of 6.31%. The stock is currently trading at $1.18 per share, with a trading volume of 10,469 shares, a turnover rate of 0.32%, and a price fluctuation of 3.71%.
Recent financial reports indicate that Artelo Biosciences has not generated any revenue and recorded a net loss of $1.13 million, resulting in an earnings per share (EPS) of -$0.35. The company's gross profit stands at $0.00, with a price-to-earnings (P/E) ratio of -0.40.
In terms of analyst ratings, all four participating institutions have given Artelo Biosciences a "buy" recommendation, with no institutions suggesting a "hold" or "sell".
Within the biotechnology sector, where Artelo Biosciences operates, the overall growth was 0.44%. Notable performers in the sector include Forte Biosciences, Inc., Klotho Neurosciences Inc C/Wts 21/06/2029 (To Pur Com), and Exicure, Inc. These stocks showed significant activity with turnover rates of 1729.53%, 1255.06%, and 890.22% respectively, and price fluctuations of 185.64%, 169.09%, and 136.94%.
Artelo Biosciences is focused on developing therapies targeting lipid signaling pathways, particularly the endocannabinoid system, which involves biochemical communication networks of receptors and neurotransmitters. The company is engaged in discovering, licensing, developing, and commercializing treatments that control this system, including proprietary cannabinoid-based therapies from both cannabis plants and synthetic cannabinoids, as well as new chemical entities and compounds. Their flagship project aims to create a patented cannabinoid drug combination therapy for rare and orphan diseases.
